Illustration of venom-derived molecules and AI-assisted analysis representing Venomics AI's drug discovery platform.
Bengaluru-based IISc spinout Venomics AI has secured $2.7 million in pre-seed funding from Speciale Invest, South Park Commons and Operators Studio. The startup will expand its Venom Atlas and develop its AI-assisted drug discovery capabilities.

Bengaluru-based biotechnology startup Venomics AI has raised $2.7 million in a pre-seed funding round co-led by Speciale Invest and South Park Commons, with participation from Operators Studio. The funding marks the company’s first institutional investment round and will support the development of its AI-powered, venom-based drug discovery platform.

Founded in 2026 by Kartik Sunagar and Vinay Prabhu, Venomics AI is a spinout of the Indian Institute of Science (IISc), Bengaluru. Sunagar, a professor at IISc, specialises in venom evolution and antivenom research, while Prabhu, the company’s co-founder and chief technology officer, brings expertise in machine learning and large-scale AI systems.

Venomics AI is developing a drug discovery platform that combines venom biology, molecular sequencing, artificial intelligence and laboratory experimentation to identify molecules with potential therapeutic applications.

Central to its approach is the Venom Atlas, a molecular dataset of compounds derived from animal venoms. The platform uses AI to prioritise promising molecules for laboratory screening, with experimental results informing subsequent predictions and molecular development.

The company plans to use the funding to expand the Venom Atlas, strengthen its AI and laboratory screening capabilities, and recruit specialists across venom biology, computational science and drug discovery. The investment will also support the validation and optimisation of potential therapeutic molecules.

Venomics AI joined the NVIDIA Inception programme in August 2026 and was selected among the five finalists for the 2026 Indo-Boston Biotech Bridge Award.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share